



Influenza Reagent
Influenza Virus Infectious IVR-237 (A/Thailand/8/2022) (H3N2)
NIBSC code: 23/206
Instructions for use
(Version 1.0, Dated 17/10/2023)

§

1. INTENDED USE

Reagent 23/206 was prepared from IVR-237 (H3N2), a reassortant of A/Thailand/8/2022 (H3N2) and A/PR/8/34 (H1N1), which was processed in 250µl volumes as liquid stock. The derivation and known passage history of 23/206 are attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom.
Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

5. STORAGE

Store in the dark at -70°C or below.
Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

N/A.

10. ACKNOWLEDGEMENTS

N/A.

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
<http://www.who.int/biologicals/en/>
JCTLM Higher order reference materials:
<http://www.bipm.org/en/committees/jc/jctlm/>
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
<http://www.nibsc.org/products/ordering.aspx>
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Clear liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify): Live influenza virus	
Toxicological properties	
Effects of inhalation:	Likelihood of influenza virus infection
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	



15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 0.25 g per vial
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable.
Attached: No

Passage history of IVR-237 (H3N2)

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E3	E3	SL10066728	VIDRL, Australia
E10	E3/E7	LOT 617B	Seqirus, Australia
E11	E3/E7/E1	47870*	MHRA, UK

* The HA titre of this virus using 0.7% guinea pig red blood cells is 1024. The infectious titre is unknown.

Sterility: No visible contamination was detected in a variety of media (tryptone soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus are available at GISAID with the accession number EPI_ISL_18399658.



REPORT

**Derivation of IVR-237
A/Thailand/8/2022 – like High Growth Reassortant**

A/Thailand/8/2022 (IVR-237) is a H3N2 high growth reassortant influenza virus.

PREPARATION

The preparation of A/Thailand/8/2022 (IVR-237) high growth reassortant influenza virus was conducted in Biopharmaceutical Product Development – FCC+ Development at CSL Seqirus.

The high yielding parent strain used was A/Puerto Rico/8/34.

MATERIALS

The following materials of biological origin were used during the preparation of high growth reassortant IVR-237:

Virus Isolate:

The virus isolate was obtained from the WHO Collaborating Centre for Reference & Research on Influenza, Melbourne (WHO-CC).

Supply details are:

A/Thailand/8/2022

WHO-CC Storage Lot number: SL10066728

Passages prior to receipt at Seqirus: 3

Eggs:

Specific Pathogen Free (SPF) eggs were used for all passages at CSL Seqirus.

Antiserum:

Trypsin-periodate treated sheep hyperimmune antiserum Lot# AS367, Sub-lot # 5041 and Sub-lot #5053, raised against influenza virus A/Puerto Rico/8/34.

The antiserum was derived from sheep born and raised in Australia.

Note on Transmissible Spongiform Encephalopathies (TSEs):

Australia and New Zealand have been declared TSE free in accordance with OIE guidelines. Detailed information on Australia's animal health status can be obtained from the following Animal Health Australia website link: <https://animalhealthaustralia.com.au>

The trypsin used is 10x solution of gamma irradiated porcine pancreatic trypsin; Gibco Cat # 15090046, Manufacturers Lot No. 2195376 and 2317956.



REPORT

TESTING OF A/THAILAND/8/2022 INFLUENZA VIRUS (IVR-237)

Test	Result		
Genotype (by real time RT-PCR)	4 : 4 (A/Puerto Rico/8/34 : A/Thailand/8/2022) Reassortant		
	A/Thailand/8/2022 (wild type virus) genes H3, N2 genes were detected.		
	A/Puerto Rico/8/34 genes NP, PA, M and PB2 were detected.		
	PB1 and NS1 genes from A/Puerto Rico/8/34 were not detected, indicating that the reassortant PB1 and NS1 genes are from A/Thailand/8/2022 (wild type virus).		
	Gene	A/Puerto Rico/8/34	A/Thailand/8/2022
	H3		✓
	N2		✓
	H1	✗	
	N1	✗	
	PB1	✗	NT
	PB2	✓	NT
	PA	✓	NT
NP	✓	NT	
M	✓	NT	
NS	✗	NT	

✓ - positive by PCR

✗ - negative by PCR

NT – Not Tested

Disclaimer:

The material i.e. high growth reassortant virus IVR-237 and the information provided in this derivation report are provided on an “as is” basis and as such without any warranty or representation of any kind (expressed or implied) including, without limitation, of satisfactory quality or fitness for a particular purpose.



REPORT

PASSAGE HISTORY:

<i>Mixed infection passage</i> (E3/D1)	A/Thailand/8/2022 wild type virus @ 10^{-3} x A/Puerto Rico/8/34 (H1N1) @ 10^{-3}	HA titre ≥ 1810
	↓	
<i>1st Antiserum Passage</i> (E3/D2)	Inoculum @ 10^{-3} with antiserum to A/Puerto Rico/8/34 (H1N1)	HA titre = 160
	↓	
<i>2nd Antiserum Passage</i> (E3/D3)	Inoculum @ 10^{-3}	HA titre ≥ 1372
	↓	
<i>3rd Antiserum/ 1st Limit Dilution Passage**</i> (E3/D4)	Inoculum @ 10^{-8}	HA titre = ≥ 1810
	↓	
<i>2nd Limit Dilution Passage</i> (E3/D5)	Inoculum @ 10^{-7}	HA titre ≥ 1810
	↓	
<i>3rd Limit Dilution Passage</i> (E3/D6)	Inoculum @ 10^{-9}	HA titre = 1194
	↓	
<i>4th Limit Dilution Passage</i> Lot 617B (E3/D7) IVR-237	Inoculum @ 10^{-5}	Mean HA titre ≥ 1701

** Virus sample diluted to 10^{-3} , dilution was mixed with antiserum to A/Puerto Rico/8/34 (H1N1) and incubated for 1 hour at room temperature. Incubated virus/antiserum sample was serially diluted and inoculated into eggs.

Total number of passages post mixed infection = 6

Total number of passages since this virus was received from an approved laboratory = 7

HA titres were determined using guinea pig red blood cells at room temperature.



REPORT

Prepared by:

Lynda Allan

Lynda Allan
Senior Scientist
Biopharmaceutical Product Development
– FCC+ Development, CSL Seqirus

Date: 01 / FEB / 2023

Authorised by:

Brad Dickson

Brad Dickson
Senior Manager
Biopharmaceutical Product Development
– FCC+ Development, CSL Seqirus

Date: 01 / FEB / 23

Content/Data check by:

Kirk Truong

Kirk Truong
Scientist
Biopharmaceutical Product Development
-FCC+ Development, CSL Seqirus

Date: 01 / FEB / 23